Fusion Toxin BLyS-Gelonin Inhibits Growth of Malignant Human B Cell Lines In Vitro and In Vivo

PLoS ONE

Volumn 7, Issue 10, 2012, Pages

  Luster, Troy A ^a   Mukherjee, Ipsita ^a   Carrell, Jeffrey A ^a   Cho, Yun Hee ^a   Gill, Jeffrey ^a   Kelly, Lizbeth ^a   Garcia, Andy ^a   Ward, Christopher ^a   Oh, Luke ^a   Ullrich, Stephen J ^a   Migone, Thi Sau ^a   Humphreys, Robin ^a  

^a GLAXOSMITHKLINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

B CELL ACTIVATING FACTOR RECEPTOR; B LYMPHOCYTE STIMULATOR GELONIN; CHLOROQUINE; GELONIN; HYBRID PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE P38; STRESS ACTIVATED PROTEIN KINASE; UNCLASSIFIED DRUG;

ACUTE LYMPHOBLASTIC LEUKEMIA; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; B CELL PRECURSOR ACUTE LYMPHOCYTIC LEUKEMIA; B LYMPHOCYTE; CANCER CELL CULTURE; CANCER INHIBITION; CANCER SURVIVAL; CELL DEATH; CONTROLLED STUDY; DOSE RESPONSE; DRUG CYTOTOXICITY; DRUG SENSITIVITY; DRUG SPECIFICITY; ENZYME ACTIVATION; FEMALE; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; INTERNALIZATION; LARGE CELL LYMPHOMA; MANTLE CELL LYMPHOMA; MOUSE; NONHODGKIN LYMPHOMA; NONHUMAN; PROTEIN EXPRESSION;

ANIMALS; B-CELL ACTIVATING FACTOR; BLOTTING, WESTERN; CELL LINE; CELL SURVIVAL; FEMALE; FLOW CYTOMETRY; HUMANS; LYMPHOMA, B-CELL; MICE; MICE, SCID; RECOMBINANT FUSION PROTEINS; RIBOSOME INACTIVATING PROTEINS, TYPE 1; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84867292358     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0047361     Document Type: Article

References (59)

1. Nardelli B, Belvedere O, Roschke V, Moore PA, Olsen HS, et al. (2001) Synthesis and release of B-lymphocyte stimulator from myeloid cells. Blood 97: 198-204.
2. Scapini P, Nardelli B, Nadali G, Calzetti F, Pizzolo G, et al. (2003) G-CSF-stimulated neutrophils are a prominent source of functional BLyS. J Exp Med 197: 297-302.
3. Tai YT, Li XF, Breitkreutz I, Song W, Neri P, et al. (2006) Role of B-cell-activating factor in adhesion and growth of human multiple myeloma cells in the bone marrow microenvironment. Cancer Res 66: 6675-6682.
4. Mackay F, Schneider P, (2009) Cracking the BAFF code. Nat Rev Immunol 9: 491-502.
5. Day ES, Cachero TG, Qian F, Sun Y, Wen D, et al. (2005) Selectivity of BAFF/BLyS and APRIL for binding to the TNF family receptors BAFFR/BR3 and BCMA. Biochemistry 44: 1919-1931.
6. Bossen C, Schneider P, (2006) BAFF, APRIL and their receptors: structure, function and signaling. Semin Immunol 18: 263-275.
7. Dillon SR, Gross JA, Ansell SM, Novak AJ, (2006) An APRIL to remember: novel TNF ligands as therapeutic targets. Nat Rev Drug Discov 5: 235-246.
8. Treml JF, Hao Y, Stadanlick JE, Cancro MP, (2009) The BLyS family: toward a molecular understanding of B cell homeostasis. Cell Biochem Biophys 53: 1-16.
9. Novak AJ, Grote DM, Stenson M, Ziesmer SC, Witzig TE, et al. (2004) Expression of BLyS and its receptors in B-cell non-Hodgkin lymphoma: correlation with disease activity and patient outcome. Blood 104: 2247-2253.
10. Novak AJ, Darce JR, Arendt BK, Harder B, Henderson K, et al. (2004) Expression of BCMA, TACI, and BAFF-R in multiple myeloma: a mechanism for growth and survival. Blood 103: 689-694.
11. Nakamura N, Hase H, Sakurai D, Yoshida S, Abe M, et al. (2005) Expression of BAFF-R (BR 3) in normal and neoplastic lymphoid tissues characterized with a newly developed monoclonal antibody. Virchows Arch 447: 53-60.
12. Onda K, Iijima K, Katagiri YU, Okita H, Saito M, et al. (2010) Differential effects of BAFF on B cell precursor acute lymphoblastic leukemia and Burkitt lymphoma. Int J Hematol 91: 808-819.
13. Parameswaran R, Muschen M, Kim YM, Groffen J, Heisterkamp N, (2010) A functional receptor for B-cell-activating factor is expressed on human acute lymphoblastic leukemias. Cancer Res 70: 4346-4356.
14. Haiat S, Billard C, Quiney C, Ajchenbaum-Cymbalista F, Kolb JP, (2006) Role of BAFF and APRIL in human B-cell chronic lymphocytic leukaemia. Immunology 118: 281-292.
15. Briones J, Timmerman JM, Hilbert DM, Levy R, (2002) BLyS and BLyS receptor expression in non-Hodgkin's lymphoma. Exp Hematol 30: 135-141.
16. Ansell SM, Armitage J, (2005) Non-Hodgkin lymphoma: diagnosis and treatment. Mayo Clin Proc 80: 1087-1097.
17. Kreitman RJ, (2009) Recombinant immunotoxins containing truncated bacterial toxins for the treatment of hematologic malignancies. BioDrugs 23: 1-13.
18. Kreitman RJ, Squires DR, Stetler-Stevenson M, Noel P, FitzGerald DJ, et al. (2005) Phase I trial of recombinant immunotoxin RFB4(dsFv)-PE38 (BL22) in patients with B-cell malignancies. J Clin Oncol 23: 6719-6729.
19. Kreitman RJ, Stetler-Stevenson M, Margulies I, Noel P, Fitzgerald DJ, et al. (2009) Phase II trial of recombinant immunotoxin RFB4(dsFv)-PE38 (BL22) in patients with hairy cell leukemia. J Clin Oncol 27: 2983-2990.
20. Kreitman RJ, Wilson WH, Bergeron K, Raggio M, Stetler-Stevenson M, et al. (2001) Efficacy of the anti-CD22 recombinant immunotoxin BL22 in chemotherapy-resistant hairy-cell leukemia. N Engl J Med 345: 241-247.
21. Veenendaal LM, Jin H, Ran S, Cheung L, Navone N, et al. (2002) In vitro and in vivo studies of a VEGF121/rGelonin chimeric fusion toxin targeting the neovasculature of solid tumors. Proc Natl Acad Sci U S A 99: 7866-7871.
22. Ran S, Mohamedali KA, Luster TA, Thorpe PE, Rosenblum MG, (2005) The vascular-ablative agent VEGF(121)/rGel inhibits pulmonary metastases of MDA-MB-231 breast tumors. Neoplasia 7: 486-496.
23. Joshi BH, Kawakami K, Leland P, Puri RK, (2002) Heterogeneity in interleukin-13 receptor expression and subunit structure in squamous cell carcinoma of head and neck: differential sensitivity to chimeric fusion proteins comprised of interleukin-13 and a mutated form of Pseudomonas exotoxin. Clin Cancer Res 8: 1948-1956.
24. Nardelli B, Moore PA, Li Y, Hilbert DM, (2002) B lymphocyte stimulator (BLyS): a therapeutic trichotomy for the treatment of B lymphocyte diseases. Leuk Lymphoma 43: 1367-1373.
25. Riccobene TA, Miceli RC, Lincoln C, Knight Y, Meadows J, et al. (2003) Rapid and specific targeting of 125I-labeled B lymphocyte stimulator to lymphoid tissues and B cell tumors in mice. J Nucl Med 44: 422-433.
26. Belch A, McEwan A, Hewitt J, Riauka T, Stabin M, et al. (2004) Tumor Targeting, Dosimetry and Clinical Response Data for Lymphorad-131 (LR131; Iodine I-131 Labeled B-Lymphocyte Stimulator) in Patients with Relapsed/Refractory Non-Hodgkin's Lymphoma. ASH Annual Meeting Abstracts 104: 750.
27. Lyu MA, Cheung LH, Hittelman WN, Marks JW, Aguiar RC, et al. (2007) The rGel/BLyS fusion toxin specifically targets malignant B cells expressing the BLyS receptors BAFF-R, TACI, and BCMA. Mol Cancer Ther 6: 460-470.
28. Lyu MA, Rai D, Ahn KS, Sung B, Cheung LH, et al. (2010) The rGel/BLyS fusion toxin inhibits diffuse large B-cell lymphoma growth in vitro and in vivo. Neoplasia 12: 366-375.
29. Nimmanapalli R, Lyu MA, Du M, Keating MJ, Rosenblum MG, et al. (2007) The growth factor fusion construct containing B-lymphocyte stimulator (BLyS) and the toxin rGel induces apoptosis specifically in BAFF-R-positive CLL cells. Blood 109: 2557-2564.
30. Lyu MA, Sung B, Cheung LH, Marks JW, Aggarwal BB, et al. (2010) The rGel/BLyS fusion toxin inhibits STAT3 signaling via down-regulation of interleukin-6 receptor in diffuse large B-cell lymphoma. Biochem Pharmacol 80: 1335-1342.
31. Stirpe F, Olsnes S, Pihl A, (1980) Gelonin, a new inhibitor of protein synthesis, nontoxic to intact cells. Isolation, characterization, and preparation of cytotoxic complexes with concanavalin A. J Biol Chem 255: 6947-6953.
32. Barbieri L, Battelli MG, Stirpe F, (1993) Ribosome-inactivating proteins from plants. Biochim Biophys Acta 1154: 237-282.
33. Wang M, Zhang L, Han X, Yang J, Qian J, et al. (2008) A severe combined immunodeficient-hu in vivo mouse model of human primary mantle cell lymphoma. Clin Cancer Res 14: 2154-2160.
34. Oren DA, Li Y, Volovik Y, Morris TS, Dharia C, et al. (2002) Structural basis of BLyS receptor recognition. Nat Struct Biol 9: 288-292.
35. Kanakaraj P, Migone TS, Nardelli B, Ullrich S, Li Y, et al. (2001) BLyS binds to B cells with high affinity and induces activation of the transcription factors NF-kappaB and Elf-1. Cytokine 13: 25-31.
36. Endo T, Nishio M, Enzler T, Cottam HB, Fukuda T, et al. (2007) BAFF and APRIL support chronic lymphocytic leukemia B-cell survival through activation of the canonical NF-kappaB pathway. Blood 109: 703-710.
37. Parameswaran R, Muschen M, Kim YM, Groffen J, Heisterkamp N A functional receptor for B-cell-activating factor is expressed on human acute lymphoblastic leukemias. Cancer Res 70: 4346-4356.
38. Pirie CM, Hackel BJ, Rosenblum MG, Wittrup KD, (2011) Convergent potency of internalized gelonin immunotoxins across varied cell lines, antigens, and targeting moieties. J Biol Chem 286: 4165-4172.
39. Varkouhi AK, Scholte M, Storm G, Haisma HJ, (2011) Endosomal escape pathways for delivery of biologicals. J Control Release 151: 220-228.
40. Mahmud H, Dalken B, Wels WS, (2009) Induction of programmed cell death in ErbB2/HER2-expressing cancer cells by targeted delivery of apoptosis-inducing factor. Mol Cancer Ther 8: 1526-1535.
41. Horita H, Frankel AE, Thorburn A, (2008) Acute myeloid leukemia-targeted toxin activates both apoptotic and necroptotic death mechanisms. PLoS One 3: e3909.
42. Iordanov MS, Pribnow D, Magun JL, Dinh TH, Pearson JA, et al. (1997) Ribotoxic stress response: activation of the stress-activated protein kinase JNK1 by inhibitors of the peptidyl transferase reaction and by sequence-specific RNA damage to the alpha-sarcin/ricin loop in the 28S rRNA. Mol Cell Biol 17: 3373-3381.
43. Narayanan S, Surendranath K, Bora N, Surolia A, Karande AA, (2005) Ribosome inactivating proteins and apoptosis. FEBS Lett 579: 1324-1331.
44. Cuenda A, Rouse J, Doza YN, Meier R, Cohen P, et al. (1995) SB 203580 is a specific inhibitor of a MAP kinase homologue which is stimulated by cellular stresses and interleukin-1. FEBS Lett 364: 229-233.
45. Clerk A, Sugden PH, (1998) The p38-MAPK inhibitor, SB203580, inhibits cardiac stress-activated protein kinases/c-Jun N-terminal kinases (SAPKs/JNKs). FEBS Lett 426: 93-96.
46. Whitmarsh AJ, Yang SH, Su MS, Sharrocks AD, Davis RJ, (1997) Role of p38 and JNK mitogen-activated protein kinases in the activation of ternary complex factors. Mol Cell Biol 17: 2360-2371.
47. Harada J, Sugimoto M, (1999) An inhibitor of p38 and JNK MAP kinases prevents activation of caspase and apoptosis of cultured cerebellar granule neurons. Jpn J Pharmacol 79: 369-378.
48. Shah SA, Halloran PM, Ferris CA, Levine BA, Bourret LA, et al. (1993) Anti-B4-blocked ricin immunotoxin shows therapeutic efficacy in four different SCID mouse tumor models. Cancer Res 53: 1360-1367.
49. Brentjens RJ, Santos E, Nikhamin Y, Yeh R, Matsushita M, et al. (2007) Genetically targeted T cells eradicate systemic acute lymphoblastic leukemia xenografts. Clin Cancer Res 13: 5426-5435.
50. Herrera L, Yarbrough S, Ghetie V, Aquino DB, Vitetta ES, (2003) Treatment of SCID/human B cell precursor ALL with anti-CD19 and anti-CD22 immunotoxins. Leukemia 17: 334-338.
51. Bendall LJ, Nilsson SK, Khan NI, James A, Bonnet C, et al. (2004) Role of CD44 variant exon 6 in acute lymphoblastic leukaemia: association with altered bone marrow localisation and increased tumour burden. Leukemia 18: 1308-1311.
52. Parameswaran R, Yu M, Lyu MA, Lim M, Rosenblum MG, et al. (2012) Treatment of acute lymphoblastic leukemia with an rGel/BLyS fusion toxin. Leukemia.
53. Weldon JE, Xiang L, Chertov O, Margulies I, Kreitman RJ, et al. (2009) A protease-resistant immunotoxin against CD22 with greatly increased activity against CLL and diminished animal toxicity. Blood 113: 3792-3800.
54. Stirpe F, (2004) Ribosome-inactivating proteins. Toxicon 44: 371-383.
55. Polito L, Bortolotti M, Farini V, Battelli MG, Barbieri L, et al. (2009) Saporin induces multiple death pathways in lymphoma cells with different intensity and timing as compared to ricin. Int J Biochem Cell Biol 41: 1055-1061.
56. Broker LE, Kruyt FA, Giaccone G, (2005) Cell death independent of caspases: a review. Clin Cancer Res 11: 3155-3162.
57. Wagner EF, Nebreda AR, (2009) Signal integration by JNK and p38 MAPK pathways in cancer development. Nat Rev Cancer 9: 537-549.
58. Roth JA, Ames RS, Fry K, Lee HM, Scannon PJ, (1988) Mediation of reduction of spontaneous and experimental pulmonary metastases by ricin A-chain immunotoxin 45-2D9-RTA with potentiation by systemic monensin in mice. Cancer Res 48: 3496-3501.
59. Van Horssen PJ, Preijers FW, Van Oosterhout YV, Eling WM, De Witte T, (2000) Relationship of the CD22 immunotoxin dose and the tumour establishment in a SCID mice model. Leuk Lymphoma 39: 591-599.